Myriad Genetics, Inc. (MYGN)

Precedente Chiudi:

$19.47

Aprire:

$19.67

Volume 24 ore:

486.78K

Capitalizzazione di mercato:

$1.74B

Reddito:

$753.20M

Utile/perdita netta:

$-263.30M

Rapporto P/E:

-5.7202

EPS:

-3.36

Flusso di cassa netto:

$-184.20M

1 W Prestazione:

+6.90%

1M Prestazione:

-3.90%

6M Prestazione:

+20.28%

1 anno Prestazione:

-9.60%

Intervallo 1D:

$19.05

$19.99

Portata 52W:

$13.82

$24.21

Myriad Genetics, Inc. Stock (MYGN) Company Profile

Nome

Myriad Genetics, Inc.

Settore

Healthcare (1190)

Industria

Diagnostics & Research (66)

Telefono

801-584-3600

Indirizzo

320 Wakara Way, Salt Lake City, UT

Dipendente

2,400

Cinguettio

@myriadgenetics

Prossima data di guadagno

2024-05-14

Ultimi documenti SEC

MYGN's Discussions on Twitter

Myriad Genetics, Inc. Stock (MYGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-21	Ripresa	Piper Sandler	Neutral
2023-12-19	Iniziato	Wells Fargo	Equal Weight
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-07-05	Ripresa	JP Morgan	Underweight
2023-05-23	Aggiornamento	Goldman	Sell → Buy
2023-01-18	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-10-06	Iniziato	Stephens	Equal-Weight
2021-10-15	Ripresa	Cowen	Market Perform
2021-06-15	Iniziato	Raymond James	Mkt Perform
2021-06-03	Iniziato	Goldman	Sell
2019-09-26	Downgrade	BofA/Merrill	Neutral → Underperform
2019-08-14	Downgrade	Piper Jaffray	Overweight → Neutral
2019-08-02	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-08-01	Aggiornamento	Barclays	Underweight → Equal Weight
2019-07-29	Downgrade	Needham	Strong Buy → Hold
2019-07-09	Downgrade	Cowen	Outperform → Market Perform
2019-03-12	Reiterato	Needham	Strong Buy
2019-01-03	Iniziato	Needham	Strong Buy
2018-11-30	Aggiornamento	Goldman	Sell → Neutral
2018-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-07-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Iniziato	Goldman	Sell
2018-01-22	Reiterato	Barclays	Equal Weight
2018-01-05	Iniziato	BTIG Research	Buy
2017-10-02	Ripresa	Leerink Partners	Mkt Perform
2017-08-09	Reiterato	Barclays	Equal Weight
2017-02-08	Aggiornamento	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Iniziato	Deutsche Bank	Sell
2016-10-10	Downgrade	Ladenburg Thalmann	Neutral → Sell

Mostra tutto

Myriad Genetics, Inc. Borsa (MYGN) Ultime notizie

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire Inc.

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Zacks Investment Research

Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

GlobeNewswire Inc.

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Zacks Investment Research

Myriad Genetics, Inc. Azioni (MYGN) Dati Finanziari

Myriad Genetics, Inc. (MYGN) Reddito 2024

Myriad Genetics, Inc. (MYGN) Reddito netto 2024

Myriad Genetics, Inc. (MYGN) Flusso di cassa 2024

Myriad Genetics, Inc. (MYGN) Utile per azione 2024